T45 Labs

Every great playbook needs a world-class leader of the field. We’re proud to name Dr. Rishi Puri, M.D., Ph.D., F.R.A.C.P. as Chief Medical Director at T45 Labs. A world-renowned interventional cardiologist, researcher, clinical trialist, and medical device innovator, Dr. Puri brings unmatched expertise in device development across coronary, structural heart, and interventional heart failure domains. With over 450 peer-reviewed publications to-date along with regular appearances on global podiums, Dr. Puri remains a driving voice in cardiovascular innovation. He will continue to work as a full-time Coronary and Structural Interventional Cardiologist at the Cleveland Clinic, and serve as an Adjunct Professor at Swinburne University of Technology, in Melbourne, Australia. Dr. Puri is both an academic and industry champion. He brings a rare breadth of expertise and accomplishments across cardiac device innovation, mechanistic research and its translation, first-in-man procedures, through to leading pivotal trials. His clinical and research career thus far spans two hemispheres and three continents, establishing him as a truly influential presence at the forefront of cardiovascular care. Please join us in welcoming Dr. Rishi Puri to T45 Labs. We are lucky to have him, and even luckier that his clarity and clinical rigor will now help shape the future of our expanding Cardiovascular Medtech device portfolio. Marwan Berrada-Sounni #T45Labs #Cardiology #MedicalInnovation #Leadership #MedTech #InterventionalCardiology

We’re excited to welcome Jeff Umscheid, SHRM-CP, CEC to T45 Labs as Senior Director of HR & Operational Strategy. Jeff brings a thoughtful, execution-focused approach to supporting growth-stage companies and building resilient teams. His experience across HR, operations, and business planning will be a key asset as we continue scaling the T45 platform. Welcome aboard, Jeff. #T45Labs #TeamGrowth #MedTechLeadership

The Founding Fathers bet on a startup called America. No blueprint. No guarantee. Just belief, grit, and timing. At T45 Labs, we like that energy. This 4th of July, we’re raising a glass to unreasonable optimism and the founders who keep betting on better. #FourthOfJuly #IndependenceDay #Medtech #Innovation #T45Labs

We’re excited to welcome Sara Royce as our new Director of Regulatory at T45 Labs. Sara brings nearly a decade of regulatory experience from the FDA, where she most recently served as Assistant Director of the Implantable Electrophysiology Devices Team. Her previous roles included Team Lead for Plaque Modification Devices and Lead Reviewer for interventional technologies. With a Ph.D. in Biomedical Engineering from Yale and a B.S. from Carnegie Mellon, Sara combines deep technical expertise with proven leadership in regulatory strategy. At T45 Labs, Sara will lead regulatory planning across our portfolio, helping bring novel cardiovascular technologies from development to clearance. Welcome aboard, Sara! We're thrilled to have you on this journey with us.

We're thrilled to see T45 Labs featured in MedTech Strategist. In this interview, founder Marwan Berrada-Sounni breaks down what makes our model tick: sharp execution, flexible capital, and a hands-on approach when it counts most. Read the full article here: https://bit.ly/44dKzu3 #medtech #medicaldevices #businessstrategies #cardiovascularcare #startups #venturecapital #T45Labs

Congratulations to our portfolio company, VahatiCor Inc, for the strong turnout and interest in its scientific symposium at #EuroPCR2025. The session focused on coronary microvascular dysfunction (CMD), an area of growing attention among interventional cardiologists, and featured perspectives from leading investigators. Speakers included Dr. Bruce Samuels, Prof. William Wijns, Dr. Bernard De Bruyne, Dr. Alexandra Lansky, Dr. Francesco Giannini, Dr. Tim van de Hoef, and Dr. Samit Shah MD, PhD, who discussed diagnostic strategies, the mechanism of reducer therapy, and the clinical development path for A-FLUX, VahatiCor’s coronary sinus reducer. T45 Labs is proud to back teams that are helping to bring scientific focus to underserved patient populations. #T45Labs #VahatiCor #EuroPCR2025 #CoronaryMicrovascularDysfunction #InterventionalCardiology #CardiovascularInnovation #Medtech

We’re excited to welcome Dr. Armando Tellez, MD, CCMP as our new Director of Clinical Affairs at T45 Labs. Armando brings extensive expertise in cardiovascular device development, having served as an SME and reviewer at the FDA’s Division of Coronary and Peripheral Interventional Devices. He is a seasoned regulatory leader with extensive experience in cardiovascular pathology, intravascular imaging, and preclinical models who brings a rigorous preclinical and clinical lens to early-stage innovation. At T45 Labs, Armando will help lead the clinical and regulatory strategy across our portfolio, driving technologies from concept to clinical validation. Welcome aboard, Armando! We’re thrilled to have you on this journey with us.

Wishing you a joyful Easter from all of us at T45 Labs. This season reminds us of renewal, resilience, and the power of hope, values that guide our work every day. Enjoy the time with loved ones and the fresh energy this season brings. #HappyEaster #SpringRenewal

We’re excited to welcome Maryam S. to the T45 Labs family as the new Electrical Engineer, Design & Quality at NuevoSono. Maryam brings hands-on experience in PCB design, embedded systems, and RF engineering for medical devices. She has contributed to a wide range of projects, from non-invasive glucose monitoring to neural signal analysis, with a focus on design, testing, and regulatory documentation. She holds a PhD in Electrical Engineering from the University of Texas at El Paso and will play a key role in advancing NuevoSono’s next-generation intravascular imaging platform. Welcome aboard, Maryam.

We’re excited to welcome Jayachandran Ravichandran, CCRP to the T45 Labs team as our new Clinical Trials Manager. Jay brings over a decade of clinical research experience across first-in-human and IDE studies in cardiology, urology, and dermatology. He has led site management and regulatory operations for early-stage programs and worked closely with cross-functional teams to drive studies forward quickly and rigorously. He joins us at a pivotal moment as multiple T45 Labs portfolio companies move toward U.S. early feasibility trials. We're glad to have him on board.